News

News 12.05.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending...

Events, External events
Event date: 14.06.2023 Mittwoch, 14. Juni 2023 - Hotel Schweizerhof Bern, Bahnhofplatz 11, 3001 Bern Das Thema der 2. Berner Tagung zum Life Science Recht sind M&A-Transaktionen im Life-Science-Sektor. Es umfasst die folgenden Schwerpunkte: Rechtsprechung: Übersicht über die aktuelle Rechtsprechung im Bereich des Life-Science-Rechts. Industriespezifische Aspekte bei der Due Diligence und der Gestaltung von...

News 08.05.2023 Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), announces the acquisition of a majority stake in DiNAMIQS, a Swiss-based company focused on the development and manufacturing of viral vectors for cell and gene therapies. Siegfried will take DiNAMIQS’...

News 27.04.2023 Schlieren (Zurich), Switzerland, April 27, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs rose 168% in the first three months of 2023, from CHF 2.0 million to CHF 5.4 million,...

News 14.04.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that further preclinical data supporting the company’s Radio DARPin Therapy Platform will be shared at the...